Biovie Completes Phase 2 SUNRISE PD Trial Enrollment for Parkinson’s Therapy | NewsOut

Published on January 13, 2026

Biotech and healthcare investors: Biovie, a clinical-stage company focused on neurological and neurodegenerative diseases, has completed enrollment in its Phase 2 SUNRISE PD clinical trial evaluating Bezisterim for early-stage Parkinson’s disease.

Reporting from the New York Stock Exchange, Jane King explains that the study enrolled 60 patients with Parkinson’s diagnosed within the past four years who have not yet been treated with carbidopa or levodopa. With enrollment complete, the company expects to analyze and report top-line results in the first half of the year.